CD8A and neoplasm: Anti-PD-1 therapy is known to activate effector CD8+ cells leading to secretion of IFN-γ which, hypothetically may decrease the number of infiltrating Tregs by suppressing tumor-induced Treg proliferation and recruitment, albeit this decrease was not statistically significant [60, 61].